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1. Introduction
Multiple myeloma (MM) or plasma cell myeloma, is a haematological disease representing
1-2% of all cancers and about 15% of haematological malignancies. The classic form of MM is
characterized by generalized neoplastic changes in the bones accompanied by kidney damage,
impaired haematopoiesis and susceptibility to infections. In laboratory tests, MM manifests it‐
self by the presence of monoclonal protein, called paraprotein, in serum or urine. This results
from the fact that pathological plasma cells produce a complete immunoglobulin (Ig), usually
IgG or IgA, or only the kappa or lambda light chains. Solitary myeloma (osseous or extraoss‐
eous), non-secretory myeloma and secretory myeloma are rarer forms of MM. Sometimes,
however, the clinical picture of MM is quite different from the classic manifestation described
in the textbooks. This can cause diagnostic difficulties, thereby delaying treatment.
The atypical clinical and laboratory manifestations and paraneoplastic syndromes concomi‐
tant with a diagnosis of MM and described below, as are those that appear in the course of
the disease, especially in progression. Although they do not represent a significant percent‐
age of cases, knowledge of the rare clinical and laboratory variants of MM may assist in
making a differential diagnosis in cases of doubt.
In addition to their low incidence, rare manifestations of MM share the lack of valid relevant
scientific knowledge, which leads to difficulties in making firm therapeutic guidelines. In
fact, most of the information on these conditions derives from case reports and/or small ser‐
ies studies, making it rather difficult to develop any uniform treatment approaches. As a re‐
sult, several of rare manifestations of MM can well be controlled with standard regimens
used for classic MM, like for example non-secretory myeloma. However the satisfactory
strategies to control some of those conditions, such as plasma cell leukemia, are still unsatis‐
factory. These issues are best illustrated in the present work in the chapter discussing PO‐
EMS syndrome.
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Furthermore, rare manifestations of MM are heterogonous also in their underlying cellu‐
lar and/or molecular mechanisms. These can be either a plasma-cell clone (non-secretory
myeloma),  paraprotein  or  cytokines  (some  of  the  paraneoplastic  disorders).  Moreover,
paraprotein  may  exhibit  autoantibody  activity  or  aggregate  into  insoluble  depositions.
This  relates  to  some other  uncommon conditions,  including various  types  of  amyloido‐
sis and cryoglobulinemia. In amyloidosis,  misfolding of proteins occurs.  Otherwise solu‐
ble,  misfolded  protein  molecules  tend  to  aggregate  as  extracellular  amyloid  fibrils,
leading to the damage of  the various tissues and organs.  In cryoglobulinemia,  parapro‐
teins present  in circulating blood can become insoluble in a  certain temperature,  result‐
ing  in  a  wide  spectrum  of  clinical  symptoms  depending  on  paraprotein  properties
(Merlini, Stone 2006).
Below, rare manifestations of MM are described in details. Their relative prevalence/inci‐
dence is given in Table 1. Table 2 provides short summary of the diagnostic and clinical
characteristics of the rare manifestations of MM, except for POEMS syndrome described in
more details in Table 3.
Rare manifestation of MM Percentage of all MM cases
Non-secretory myeloma 1-5%
Myeloma IgD, IgM and IgE
IgD 2%
IgM 0.2-0.5%
IgE Very rare
Plasma cell leukemia 0.5-3.0%
POEMS syndrome Very rare
Rare paraneoplastic syndromes
accompanying myeloma
Extremely rare
Family myeloma Extremely rare
Supporting references can be found in corresponding sections of the main text.
Table 1. Rare manifestations of multiple myeloma (MM) and their prevalence/incidence.
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Rare manifestation of MM Major diagnostic criteria
Non-secretory myeloma Bone marrow cytology and immunohistochemistry: the infiltration of
clonal plasma cells.
The clinical picture: classic osteolytic lesions and a decrease in the level of
normal (non-clonal) immunoglobulins.
Myeloma IgD Diagnosis: problematic because routine test does not detect the
monoclonal protein peak in 60% of patients, and when it is detected, the
concentration is usually smaller than 20 g/l. An overproduction of light
chains (usually lambda) is observed in 90-96% of patients.
The clinical picture: a variant of the light chain disease. Usually affects
younger patients, the disease course is more aggressive and often
accompanied by amyloidosis and extramedullary infiltrations.
Lymphadenopathy, renal failure and hypercalcemia are common.
Myopathy and carpal tunnel syndrome can be present.
Myeloma IgM Diagnosis: the presence of IgM monoclonal protein in serum; it is
necessary to differentiate with Waldenström's macroglobulinemia.
The clinical picture: the clonal proliferation of plasma cells in bone marrow
aspiration and the presence of hypercalcemia, renal failure and osteolytic
foci.
Myeloma IgE Frequent presence of plasma cells in peripheral blood, osteoblastic lesions,
hepatosplenomegaly and amyloidosis.
Plasma cell leukemia Diagnosis: at least 20% plasma cells in a peripheral blood smear and/or
the absolute number of plasma cells in the peripheral blood exceeding 2
g/l with a concomitant monoclonal gammopathy.
The clinical picture: extraosseous infiltrations, often with the involvement
of the central nervous system, and accompanied by organomegaly and
lymphadenopathy.
Rare paraneoplastic syndromes
accompanying myeloma
Sweet’s syndrome: granolocytosis, fever and painful erythematous skin
changes caused by skin granulocytic infiltrations that subside following
treatment with corticosteroids.
Bullous epidermal separation or pemphigus: subepidermal bubbles and
secondary ulcers.
Family myeloma The exact genetic cause remains unknown but autosomal inheritance with
low gene penetrance is most probable.
An annual immunoelectrophoresis of the urine and serum protein least
two cases of MM in first or second-degree relatives are present.
Supporting references can be found in corresponding sections of the main text. Detailed diagnostic criteria of POEMS
syndrome can be found in Table 3.
Table 2. Major diagnostic procedures and criteria of rare manifestations of multiple myeloma (MM).
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Disease Definitionof the disease References
POEMS
syndrome
All four criteria must be met:
1. The presence of the monoclonal protein (in serum and/or in urine),
especially the light chain type λ.
2. Peripheral polyneuropathy.
3. The presence of at least one "great" criterion:
• osteosclerotic changes in the skeletal system
• Castleman's disease
• high levels of vascular endothelial growth factor.
4. The presence of at least one "small" criterion:
• the enlargement of the internal organs (liver, spleen, lymph nodes)
• pleural effusion, ascites, oedema
• abnormal secretion of the endocrine glands (adrenal glands, thyroid,
parathyroid, pancreas, gonads, with the exception of diabetes or
hypothyroidism)
•skin lesions (hyperpigmentation, hypertrichosis, peripheral cyanosis,
abnormal structure of the nails)
• optic disc oedema,
• thrombocythaemia, polycythemia.
Kyle et al. 2009 Dispenzieri
et al. 2003
Dispenzieri et al. 2007
Rajkumar et al. 2011
Table 3. The criteria for diagnosis of POEMS syndrome.
2. Non-secretory myeloma
Non-secretory myeloma is one of the least frequent forms of MM. The classic diagnostic
methods of immunoelectrophoresis and immunofixation do not detect any monoclonal pro‐
tein in either urine or serum. These patients are usually referred to a haematologist as part
of a diagnosis for anaemia or bone changes. It is estimated that this form represents 1-5% of
all MM cases [Kyle et al. 2003, Blade, Kyle 1999]. The diagnosis is based on a bone marrow
examination (cytology and immunohistochemistry). This will confirm the infiltration of clo‐
nal plasma cells, although immunohistochemical tests do not confirm the existence of light
kappa or lambda chains in 15% of patients with non-secretory myeloma. The clinical picture
reveals classic osteolytic lesions and a decrease in the level of normal (non-clonal) immuno‐
globulins [Kyle et al. 2003, Blade, Kyle 1999] in 92% of patients. Although classic diagnostic
tests do not indicate the presence of monoclonal protein, the ratio of free light chains in se‐
rum (FLCr) is abnormal in more than 2/3 of patients. This test is recommended for these pa‐
tients to evaluate the effectiveness of the therapy [Durie 2006, Dispenzieri 2009]. A more
detailed analysis of the immunofixation test, together with the results of the test for free
light chains, allows the presence of monoclonal protein in serum to be ascertained. The pro‐
portion of patients with "true" non-secretory myeloma is consequently found to be much
smaller than 2%. Repeated bone marrow smear tests are the only way to assess the activity
of the disease [Durie 2006] in these patients. Cytogenetic abnormalities in patients with non-
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secretory myeloma do not differ from those observed in the secretory form [Blade, Kyle
1999]. Both the prognosis and the therapeutic recommendations are the same for patients
with non-secretory myeloma and the classic form of the disease, i.e. secretory myeloma.
Some studies, however, indicate that the prognosis for patients with non-secretory myeloma
treated using autologous transplantation is better than for the patients suffering from the
classic form of the disease [Terpos et al. 2003].
3. Myeloma IgD, IgM and IgE
The monoclonal production of immunoglobulin IgD A is a rare laboratory manifestation of
MM, observed in approximately 2% of patients with MM. Diagnostic problems arise from
the fact that the routine test does not detect the monoclonal protein peak in 60% of patients,
and when it is detected, the concentration is usually smaller than 20 g/l. An overproduction
of light chains (usually lambda) is observed in 90-96% of patients. This makes the clinical
picture a variant of the light chain disease [Blade, Kyle 1999, Kuliszkiewicz-Janus et al. 2005,
Shimamoto, 1991, Blades et al. 1994, Jancelewicz et al. 1975]. The clinical picture is also
slightly different, although this usually affects younger patients – the disease course is more
aggressive and often accompanied by amyloidosis and extramedullary infiltrations. Lym‐
phadenopathy is observed in 10% of patients [Shimamoto, 1991, Blades et al. 1994]. Renal
failure is observed in 33% of cases at the moment of diagnosis and hypercalcemia in 20%
[Homan et al. 1990]. The disease is often accompanied by neurological symptoms such as
myopathy and carpal tunnel syndrome, which is probably associated with the coexistence of
amyloidosis. IgD myeloma is often associated with connective tissue diseases. This can hin‐
der diagnosis due to the resulting low concentration of monoclonal protein. Previous analy‐
ses suggest that the mean survival time of patients with IgD MM is 13.7-21 months. This is
shorter than for the classic IgG and IgA MM [Blade et al. 1994, Jancelewicz et al. 1975]. More
recent analyses, however, indicate that 30% of patients with IgD myeloma live more than 3
years and 20% more than 5 years [Blade et al. 1994]. Shimamoto regards the presence of the
lambda chain and leukocytes in excess of 7 g/l as adverse factors responsible for the shorter
progression-free time in patients with IgD MM. Depending on the number of prognostic fac‐
tors, patients are classified into three prognostic groups: 0, 1 and 2 [Shimamoto et al. 1991].
Based on a retrospective analysis of 36 patients undergoing ablative chemotherapy, the
probability of 3-year survival and progression-free time were 69% and 38% respectively
[Sharma et al. 2010]. Some authors indicate that the use of myeloablative chemotherapy re‐
duces the differences between IgD MM and the classic forms of the disease [Sharma et al.
2010, Maisnar et al. 2008], but this remains a matter for discussion [Morris et al. 2010].
MM IgM is even less frequent (0.2-0.5% of patients with MM) [Reece et al. 2010, MacLennan
1992, Avet-Loiseau et al. 2003]. Although the presence of IgM monoclonal protein in serum
is one of the clinical features common to the disease and Waldenström's macroglobulinemia
(WM), the overall clinical picture is different. The differing prognoses and therapeutic rec‐
ommendations make a correct diagnosis all the more important. The clonal proliferation of
plasma cells usually observed in bone marrow aspiration, together with other characteristic
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clinical features of multiple myeloma such as hypercalcemia, renal failure and osteolytic fo‐
ci, support a diagnosis of IgM MM much more frequently than a diagnosis of WM. These
differential diagnostics may not be easy. Cytogenetic tests are helpful in these situations. Re‐
cent study results indicate that the presence of translocation t(11;14) associated with deregu‐
lation of cyclin D1 is specific for MM, but not for WM [Avet-Loiseau et al. 2003]. Another
differentiating feature is that 6q deletion istypical of WM [Schop et al. 2006]. Some authors,
however, indicate the limited sensitivity of cytogenetic testing in diagnosing MM IgM and
therefore seek other differential diagnostic tests [Schuster et al. 2010]. One would be an in‐
creased expression of interleukin-1b (IL-1b). This substance is responsible for the increased
production of interleukin 6 (IL-6) reported in patients with MM [Donovan et al. 2002]. The
treatment of patients with IgM MM does not differ substantially from the treatment of pa‐
tients with the classic form of MM. Some studies however, indicate a significantly worse
prognosis compared with the classic forms, i.e. a much shorter survival time and progres‐
sion-free time in patients with the rare form of MM [Morris et al. 2010]. Mean survival time
is 30 months and myeloablative chemotherapy does not alter this prognosis [Reece et al.
2010, Schuster et al. 2010].
IgE myeloma is very rarely detected. Several cases of this variant have been described [In‐
vernizzi et al. 1991, Hagihara et al. 2010, Chiu et al. 2010]. It manifests itself by the frequent
presence of plasma cells in peripheral blood, osteoblastic lesions, hepatosplenomegaly and
amyloidosis. The clinical course of this form of MM is usually aggressive and patients have
a shorter survival time than those with the classic forms (16 months on average). This may
be a result of a delayed diagnosis [Macro et al. 1999].
4. Plasma cell leukaemia
Plasma cell leukaemia is one of the most aggressive forms of MM. It is defined according to
the Kyle criteria. Diagnosis is predicated on there being at least 20% plasma cells in a pe‐
ripheral blood smear and/or the absolute number of plasma cells in the peripheral blood ex‐
ceeding 2 G/l with a concomitant monoclonal gammopathy [Sher et al. 2010, Jimenez-
Zepeda]. It should be noted that the presence of plasma cells in peripheral blood is
symptomatic of several infectious diseases, e.g. septic shock, parvovirus B19 infection, infec‐
tious mononucleosis, and Dengue fever. These diseases, however, are not accompanied by
the presence of monoclonal protein and the plasmacytosis abates with the other symptoms
[Gawoski, Ooi 2003, Bai et al. 2006].
Plasma cell leukaemia is rare. It is estimated to constitute 0.5-3% of MM [Han et al. 2008].
Two forms of the disease should be distinguished: a primary form identified in the initial
diagnosis; and a secondary form symptomatic of pre-existing classic MM. The primary form
was more frequent than the secondary in previous analyses, but the number of patients with
the primary and secondary forms is now similar [Sher et al.]. Complex cytogenetic abnor‐
malities are found in 70% of cases of plasma cell leukaemia. These usually include hypodi‐
ploidia and structural abnormalities of chromosomes 1, 13 and 14 that are similar in both
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forms of the disease [Fonseca et al. 2004, Chang et al. 2009, Colovic et al. 2008]. Plasma cell
leukaemia is the most aggressive clinical form of MM. Patients usually manifest extraoss‐
eous infiltrations, often with the involvement of the central nervous system, and accompa‐
nied by organomegaly and lymphadenopathy. The aggressiveness of the disease is also
demonstrated by the significantly increased activity of serum lactate dehydrogenase, high
levels of β2-microglobulin (in 65% of patients > 6 mg/l) and low serum albumin levels.
The prognosis remains poor, especially in the secondary form, where it is a consequence of
the progression of the disease and increasing chemoresistance. Moreover, resistance very
quickly develops in patients with primary leukaemia, despite their initial response to treat‐
ment. The average survival time is 8 months for patients with the primary form and 2
months for those with the secondary form [Garcia-Sanz et al. 1999, Tiedemann et al. 2008].
Because of the low incidence of the disease, there are no randomized controlled trials and
thus no therapeutic recommendations. Traditional schemes for treatment of MM are usually
ineffective. Even though prolongation of survival time was reported in patients after mye‐
loablative chemotherapy assisted by autotransplantation, this treatment was less effective
than it was in patients with the classic form of the disease. Allotransplantation is an alterna‐
tive, especially in the primary disease, which often affects younger people. Due to the limit‐
ed number of patients and lack of randomized studies, the effects of this treatment are
difficult to assess, but previous reports indicate moderate effectiveness and high mortality
(the mean survival time is 3 months) [Yeh et al. 1999].
New drugs, such as proteasome inhibitors and immunomodulatory drugs, are promising,
although the effectiveness of this treatment remains unsatisfactory. As thalidomide is of lim‐
ited efficacy and seems to have no significant effect on prolonging survival time in patients
with plasma cell leukaemia (reported mean survival time is 3 months) [Petrucci et al. 2007],
other authors have been presenting more promising data (survival time up to 14 months)
[Johnston, Abdalla 2002]. The use of lenalidomide has enabled a response to be obtained in
individual patients, as with resistance to other schemes, but this usually lasts 4-5 months
[Musto et al. 2008, Benson and Smith 2007]. The results of bortezomib treatment are slightly
more promising. This therapy, especially the combination therapy (VDT-PACE), enables a
response to be obtained in more than 90% of patients, including those in whom the disease
is initially chemoresistant. Mean survival time is 7-12 months [Albarracin, Fonseca 2011,
Musto et al. 2007], although survival times of up to 20 months have also been reported [Sher
et al. 2010, Ali et al. 2007]. Bortezomib appears to be able to overcome the adverse effects of
cytogenetic abnormalities [Katodritou et al. 2009] – as it does with classic MM – and should
therefore be considered a first-line treatment in patients with plasma cell leukaemia.
5. POEMS syndrome
The syndrome was first described in 1956 and was originally named the Crow–Fucasi syn‐
drome. Since 1980, it has been known by the acronym POEMS, derived from the symptoms
polyneuropathy, enlarged internal organs (organomegaly), endocrine disorders, monoclonal
protein and skin changes.
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The pathogenesis of POEMS syndrome is complex and not fully understood. The starting
point must be the mutation of the plasma cells producing the light chains (usually λ) as this
is what causes its clonal expansion. Karyotype tests of plasma cells usually reveal aneuploi‐
dy [Rose et al. 1997] and del13 [Bryce et al. 2007]. Whether a neoplastic clone produces its
characteristic symptoms through the direct action of monoclonal protein on some target
molecules and the secretion of various cytokines from neoplastic cells, or whether it hap‐
pens in an indirect manner, is not precisely known. It is believed that high levels of pro-an‐
giogenic and pro-inflammatory cytokines, especially IL-1β, TNF-α, IL-6 and a concentration
of vascular endothelial growth factor (VEGF) are essential to the development of the clinical
symptoms of POEMS syndrome [Gherardi et al. 1996, Hitoshi et al. 1994].
VEGF is considered to be the most important cytokine responsible for the development of
POEMS syndrome. This is the cytokine that reacts with endothelial cells and causes the rap‐
id and reversible increase in vascular filtration essential to angiogenesis and osteogenesis
[Endo et al. 2002, Soubrier et al. 1997]. The increased production of VEGF is also a result of
high concentrations of IL-1 and IL-6 [Soubrier et al. 1997]. VEGF 165 isoform is most com‐
monly diagnosed. The concentration of VEGF correlates with the progression of the disease,
but does not depend on the concentration of monoclonal protein [Watanabe et al. 1998].
POEMS syndrome is very rare. The incidence in Japan is 3 cases per million people per year
[Arimura et al. 2007], and this is estimated to be even less in Western Europe and the United
States of America. The peak incidence of POEMS syndrome occurs during the fifth and the
sixth decades of life [Dispenzieri et al. 2007]. POEMS syndrome is a chronic disease and
some patients live more than 10 years. Dispenzieri et al. have found that the mean survival
time of patients with POEMS is 13.8 years [Dispenzieri et al. 2003]. In turn, Gherardi et al.
have found that 7 out of 15 patients with POEMS syndrome live 5 years or more, including
one case of 25 years [Gherardi et al. 1991].
The criteria for diagnosing POEMS syndrome are summarized in Table 3.
The characteristic symptoms of POEMS syndrome should have a temporal relationship. The
most important symptom, i.e. the one that enables POEMS to be differentiated from other
plasma cell dyscrasias, is the ascertainment of single or multiple osteosclerotic changes. A
conclusive diagnosis of POEMS syndrome is unlikely in the absence of bone changes. Skin
changes, most commonly hypertrichosis and hyperpigmentation, may occur in POEMS pa‐
tients. Enlarged mammary glands and testicular atrophy may occur in men. Peripheral
blood count abnormalities, especially thrombocythemia and polyglobulia, are frequently de‐
tected by morphological examinations.
The concentrations of serum monoclonal protein and the level of Bence-Jones protein in
urine are lower than in patients with MM. Renal failure, high calcium plasma concentration,
and pathological bone fractures are rarely observed. The percentage of plasma cells is usual‐
ly less than 5% in bone marrow examinations. High concentrations of IL-1β, TNF-α, IL-6
and VEGF in serum are typical of POEMS [Soubrier et al. 1997].
Polyneuropathy is the predominant clinical symptom (100% of patients with POEMS syn‐
drome) [Kelly Jr. et al. 1983]. Initially, sensory disturbances occur mainly in the lower limbs.
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Gait disorders may appear later. This process is progressive and movement is difficult in
50% of patients. This can eventually cause disability. Bone pain and pathologic fractures are
rare. Other symptoms include progressive weight loss and muscle atrophy.
About 1/3 of patients develop ascites and fluid in the pleural cavities [Dispenzieri et al.
2007]. In 50% of patients, the liver, and less frequently the spleen and the lymph nodes, is
enlarged. A histopathological examination of the enlarged lymph node often indicates an‐
giofollicular lymph node hyperplasia (Castleman's disease) [Dispenzieri et al. 2003, Naka‐
nishi et al. 1984]. Some patients may develop venous and arterial thrombosis [Kang et al.
2003]. Impaired secretion of endocrine glands, most commonly hypogonadism, hypothyr‐
oidism, glucose metabolism and adrenal insufficiency, is diagnosed in about 84% of pa‐
tients. Most patients have impaired secretion in four or more endocrine glands. This may be
accompanied by failure of the gonads, thyroid, pancreas and adrenal glands.
Because the predominant symptom is polyneuropathy, patients with POEMS syndrome are
initially referred to neurologists - usually with suspected Guillain-Barré syndrome or chron‐
ic inflammatory demyelinating polyradiculoneuropathy.
Once the monoclonal protein accompanying the polyneuropathy has been detected, a differ‐
ential diagnosis should include AL, monoclonal gammopathy and MM.
The concentration of VEGF is one of the most sensitive tests to differentiate POEMS syn‐
drome from the other diseases mentioned above. The plasma of patients with POEMS syn‐
drome has a high VEGF concentration. VEGF concentration in patients with the other
diseases mentioned above is low [Gherardi et al. 1996, Watanabe et al. 1998].
The rare incidence of POEMS syndrome and the lack of definitive knowledge as to its causes
mean that there are no standards of treatment. For the same reason, there are no random‐
ized clinical trial results to evaluate the effectiveness of any given method of treatment.
Methods of treating POEMS syndrome patients have mainly been devised from clinical re‐
ports, case reports and retrospective observations (usually at a single centre), and the experi‐
ence gained from treating other plasma cells dyscrasias.
Radiotherapy is the treatment of choice for POEMS syndrome patients with isolated bone
lesions. If there are numerous bone changes and these coexist with other symptoms typical
of POEMS syndrome, it is recommended that patients be treated similarly to those with
MM. In older patients, the treatment is based on alkylating drugs, while the therapy for
younger patients includes high-dose chemotherapy-assisted auto-SCT [Dispenzieri et al.
2003].
The final confirmation of the hypothesis that VEGF is the major cytokine responsible for the
development of POEMS syndrome, will have a significant impact on changing the way that
POEMS patients are treated; the way which will be predominantly focused on VEGF..Nei‐
ther intravenous immunoglobulins nor plasmapheresis treatments benefit patients with PO‐
EMS syndrome [Dispenzieri et al. 2007]. The concomitant treatment with plasmapheresis
and corticosteroids was found to be more effective [Ku et al. 1995]. Melphalan is the drug
that has been used to treat dyscrasias the longest. The results of retrospective studies, in
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which melphalan was mainly used in combination with prednisone (the treatment duration
was 12-24 months), indicate that a response to the treatment was obtained in 40% of patients
[Dispenzieri et al. 2003]. Cyclophosphamide allows for remission of the disease in a limited
number of patients. This treatment may be used in young patients who are candidates for
auto-SCT.
The results of high-dose chemotherapy-assisted auto-SCT are promising [Sanada et al. 2006],
as a response is obtained in over 90% of patients (Table 4). Transplant related mortality is
determined to be approximately 7%. This is higher than in MM patients treated with auto-
SCT and lower than in AL patients treated with auto-SCT [Gertz et al. 2002]. High dose che‐
motherapy assisted auto-SCT reduces the symptoms of polyneuropathy. When combined
with radiotherapy, this reduction can last months or even years [Ganti et al. 2005]. The clini‐
cal response to the treatment correlates more closely to the VEGF concentration than to the
monoclonal protein level [Nakano et al. 2001]. A complete haematological remission is not re‐
quired to obtain a clinical improvement. The effectiveness of the most common ways of
treating patients with POEMS syndrome is shown in Table 4.
Treatment Response to the treatment References
Corticosteroids ≥15% Dispenzieri et al. 2003
Nakanishi et al. 1984
Orefice et al. 1994
Treatment with alkylating drugs ≥40% Dispenzieri et al. 2003
Reitan et al. 1980
Radiation therapy ≥50% Dispenzieri et al. 2003
Iwashita et al. 1977
Reitan et al. 1980
Auto-SCT ≥90% Sanada et al. 2006
Ganti et al. 2005
Jaccard et al. 2002
Auto-SCT (auto-stem cells transplantation) – autologous transplantation of the stem cells obtained from peripheral
blood.
Table 4. The effectiveness of the most commonly used treatments in patients with POEMS syndrome.
Apart from the methods of treating POEMS syndrome mentioned above, there are few re‐
ports on the effectiveness of therapy combined with bevacizumab and thalidomide in pa‐
tients diagnosed with a relapse of POEMS syndrome after auto-SCT. The combination of
cyclophosphamide, dexamethasone and bevacizumab is another example of a modern com‐
bination therapy, described by Samaras et al., to treat POEMS syndrome relapse after auto-
PBSCT [Badros et al. 2005, Straume et al. 2006]. There are also case reports describing the
treatment of patients with POEMS syndrome using lenalidomide [Dispenzieri et al. 2007].
Recently, Szturz et al. [2012] reported on the successful application of lenalidomide in Cas‐
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tleman disease, a condition that can accompany POEMS syndrome. Other drugs used to
treat POEMS syndrome patients include interferon α [Coto et al. 1991], tamoxifen, trans reti‐
noic acid, thalidomide, ticlopidine, argatroban and strontium (89Sr) [Dispenzieri et al. 2007].
The effectiveness of these drugs is limited and further clinical trials are required.
Lenalidomide seems to be one of the most promising immunomodulatory drugs to treat PO‐
EMS syndrome, but further clinical studies are required [Dispenzieri et al. 2007].
High dose chemotherapy assisted auto-SCT remains the best therapeutic method, although
it also has the highest mortality rate.
6. Rare paraneoplastic syndromes accompanying myeloma
Sweet’s syndrome is one of the paraneoplastic syndromes that may accompany MM. This is
a group of symptoms including granolocytosis, fever and painful erythematous skin
changes caused by skin granulocytic infiltrations that subside following treatment with corti‐
costeroids [Paydas et al. 1993]. These changes are also found in the mouth, the joints and the
internal organs. Sweet's syndrome is extremely rare (0.25% of patients with MM) and is
most likely caused by an increased sensitivity to the growth factor. This can be explained by
an increased production of interleukin 6 (IL-6) [Bayer-Garner, Cottler-Fox, Smoller 2003].
Bullous epidermal separation (epidermolisis bullosa) may also coexist with MM. This is as‐
sociated with the production of IgG antibodies against the non-collagenous domain of type
VII collagen. This leads to the formation of subepidermal bubbles and secondary ulcers
[Radfar 2006]. Pemphigus has a similar clinical picture. This is a rare complication observed
in MM patients and is usually associated with IgA MM. This disease develops extremely
rarely and is sometimes also associated with gammopathy of undetermined significance. It
has been suggested that treatment should include bortezomib [Adam et al. 2010]. There are
many skin symptoms associated with monoclonal gammopathy: leukocytoclastic vasculitis,
pyoderma gangrenosum and Schnitzler syndrome. These, however, are rare and discussing
them is beyond the scope of this chapter [Harati et al. 2005].
7. Family myeloma
The cause of MM remains unknown [Lynch et al. 2008, Alexander et al. 2007, Morgan, Da‐
vies, Lineta 2002]. It seems that the hereditary cause is negligible, although family cases of
this cancer have been observed. It has also been described in connection with gammopathy
of undetermined significance [Lynch et al. 2008]. Large population studies also indicate that
MM, prostate cancer and malignant melanoma run in families, as do central nervous system
neoplasms, although the results of some studies do not confirm this [Eriksson, Hallberg
1992, Camp, Werner, Cannon-Albright, 2008]. The risk of familial MM is small. It is estimat‐
ed that the probability of first-degree relatives developing MM is 3.2 per 1000 cases and
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women are usually affected. Autosomal inheritance with low gene penetrance is believed to
be responsible for the onset of the disease. The risk of familial gammopathy of undeter‐
mined significance is slightly higher, although still small. Had there been at least two cases
of MM in first or second-degree relatives, an annual immunoelectrophoresis of the urine
and serum protein in people 40 years and over would be recommended. If MM had occur‐
red in anyone under 40 years old, the test would be recommended to relatives 35 years and
over [Gerkes et al. 2007].
The described forms of MM are extremely rare. They are an important diagnostic problem
because of their atypical clinical manifestation. The course of the disease is usually aggres‐
sive and the prognosis is serious. It is therefore essential that it be quickly and accurately
diagnosed. The lack of prospective studies of large groups of patients is an additional prob‐
lem. This makes these atypical clinical forms a therapeutic as well as a diagnostic challenge.
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